Search results
To Your Good Health: The cause behind a case of CMML seems to be unknown
The Marshall News Messenger· 7 hours agoAccording to his death certificate, he died of lung cancer (not a surprise) and chronic...
EXCLUSIVE: Woman is turned away by multiple doctors before they realize she has cancer
Today· 1 hour agoAround 2016, Mary Witkop noticed a bump on the inside of her right knee. “I saw probably five or six...
NHS genomics testing will be vital in supporting personalised cancer trials
Clinical Trials Arena via Yahoo Finance· 13 hours agoThe second trial, which has been recently launched by the NHS in collaboration with BioNTech, is...
The Case for Buying Iovance Biotherapeutics Stock Just Got Even Better. Here's Why
Motley Fool via Yahoo Finance· 4 days agoAnd therein lies the exciting new data. In case you aren't familiar, the most widely used...
Summit (SMMT) Stock Surges 57% in the Past Month: Here's Why
Zacks via Yahoo Finance· 2 days agoSummit Therapeutics (SMMT) surges after data from a late-stage study shows that its experimental...
Is Moderna Stock A Buy After Its Second-Ever Product Snags FDA Approval?
Investor's Business Daily· 2 days agoModerna will rival Pfizer and GSK, which launched their shots last year. Also, in June, Moderna and...
3 Reasons to Buy Moderna Stock
The Motley Fool via AOL· 6 days agoMerck is one of the leading oncology-focused drugmakers in the world, largely thanks to Keytruda, a medicine that has earned dozens of approvals for...
Is Merck & Co. Inc. (NYSE:MRK) The Best Healthcare Stock to Buy in 2024?
Insider Monkey via Yahoo Finance· 1 day agoWe recently published a list entitled Billionaire Israel Englander’s Top 10 Stock Picks for 2024....
Top Analyst Reports for Microsoft, Apple & Alphabet
Zacks via Yahoo Finance· 2 days agoToday's Research Daily features new research reports on 16 major stocks, including Microsoft Corporation (MSFT), Apple Inc. (AAPL) and Alphabet Inc....
J&J-backed Bright Peak secures $90m to advance immunoconjugate programme
Pharmaceutical Technology via Yahoo Finance· 2 days agoThe PD-1 inhibitor landscape is currently dominated by MSD’s Keytruda (pembrolizumab) and Bristol...
